1. Inicio
  2. Publicaciones
  3. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study

Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Phan D.B.
  • Jourdain H.
  • Descalzo-Gallego M.A.
  • González-Quesada A.
  • Zureik M.
  • Rivera-Díaz R.
  • Lunt M.
  • Garcia-Doval I.
  • Sbidian E.
  • Warren R.B.
  • Yiu Z.Z.N.

Grupos

Abstract

Background The lack of evidence from routine clinical settings has limited the widespread adoption of adalimumab biosimilars for the treatment of psoriasis. Objectives To compare the drug survival and safety of adalimumab biosimilars with Humira® in psoriasis. Methods We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM). Adalimumab-naïve patients initiating adalimumab biosimilars (new users) were compared with Humira new users. Patients switching from Humira to biosimilars (switchers) were compared with those who continued Humira treatment. Patients were matched 1 : 1 based on previous adalimumab exposure time to create equal-sized cohorts of biosimilar and Humira users. Co-primary outcomes included drug discontinuation and serious adverse events (SAEs). Hazard ratios (HRs) were calculated using Cox proportional hazard models. Meta-analyses using random-effect models were performed to combine results from the three databases. Results In total, 7387 biosimilar new users and 3654 switchers were matched and compared with Humira users. No differences in all-cause discontinuation were found between biosimilar and Humira new users [HR 0.99, 95% confidence interval (CI) 0.94–1.04]. Switching from Humira to biosimilars was associated with a higher discontinuation rate than remaining on Humira (HR 1.35, 95% CI 1.19–1.52). Similar results were observed for discontinuation due to ineffectiveness or adverse events. Risks of SAEs were similar between biosimilar new users and Humira new users [incidence rate ratio (IRR) 0.91, 95% CI 0.80–1.05] or between switchers and continuous Humira users (IRR 0.92, 95% CI 0.83–1.01). Conclusions Adalimumab biosimilars can be considered viable alternatives to Humira for new patients, with comparable effectiveness and safety. However, owing to the higher likelihood of discontinuation, patients who switch from Humira to biosimilars may require closer monitoring and support. © The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.

Datos de la publicación

ISSN/ISSNe:
0007-0963, 1365-2133

BRITISH JOURNAL OF DERMATOLOGY  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
641-652
PubMed:
39565180
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,447 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acitretin; adalimumab; apremilast; biosimilar agent; cyclosporine; deucravacitinib; fumaric acid; methotrexate; tofacitinib; adult; Article; benign neoplasm; cohort analysis; comparative effectiveness; drug exposure; drug safety; drug substitution; drug withdrawal; female; human; incidence; major clinical study; male; malignant neoplasm; middle aged; multicenter study (topic); outcome assessment; psoriasis; risk assessment; skin disease; survival analysis; systemic therapy; treatment switching

Cita

Compartir